Диагностика нарушений гемостаза и принципы их коррекции при тромботических осложнениях в онкологии
Диссертация
У онкологических больных с тромбозами установлена выраженная гиперкоагуляция с признаками активного внутрисосудистого свертывания крови. Определяется существенное укорочение АЧТВ, высокая концентрация фибриногена, РКМФ, Д-димера, фактора Виллебранда на фоне резкого снижения протеина С и плазминогена. Применение низкомолекулярных гепаринов у онкологических больных с тромбозами на фоне химиотерапии… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. НАРУШЕНИЯ СИСТЕМЫ ГЕМОСТАЗА У
- ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ (Обзор литературы)
- 1. 1. Опухоль и система гемостаза
- 1. 2. Хирургическое лечение и система гемостаза
- 1. 3. Химиотерапия и система гемостаза
- 1. 4. Низкомолекулярные гепарины в профилактике и лечении нарушений системы гемостаза и тромботических осложнений
- 1. 5. Гепарин и выживаемость онкологических больных
- ГЛАВА 2. МАТЕРИАЛЫ И МЕТОДЫ
- 2. 1. Общая характеристика больных
- 2. 1. 1. Клиническая характеристика больных опухолями опорно -двигательного аппарата
- 2. 1. 2. Специфическая профилактика нарушений системы гемостаза и тромботических осложнений у больных опухолями опорно — двигательного аппарата
- 2. 1. 3. Клиническая характеристика больных онкологическими заболеваниями органов женской половой системы
- 2. 1. 4. Специфическая профилактика нарушений системы гемостаза и тромботических осложнений у онкогинекологических больных
- 2. 1. 5. Клиническая характеристика онкологических больных, получающих химиотерапию
- 2. 1. 6. Специфическая профилактика и лечение нарушений системы гемостаза и тромботических осложнений у онкологических больных, получающих химиотерапию
- 2. 1. 7. Клиническая характеристика онкологических больных с тромбозами и тромбоэмболией легочной артерии, развившимися на фоне подострого ДВС крови
- 2. 1. 8. Сравнительная характеристика низкомолекулярных' гепаринов
- 2. 2. Методы исследования системы гемостаза
- 2. 3. Характеристика использованных статистических методов и технических средств
- 2. 1. Общая характеристика больных
- ГЛАВА 3. ПРОФИЛАКТИКА НАРУШЕНИЙ СИСТЕМЫ ГЕМОСТАЗА И ПОСЛЕОПЕРАЦИОННЫХ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ ОПУХОЛЯМИ ОПОРНО -ДВИГАТЕЛЬНОГО АППАРАТА
- 3. 1. Состояние системы гемостаза у больных опорно-двигательного аппарата до операции
- 3. 2. Влияние клексана на систему гемостаза у больных опухолями опорно- двигательного аппарата
- 3. 3. Тромботические осложнения в послеоперационном периоде у больных опухолями опорно-двигательного аппарата
- 3. 4. Оценка эффективности и безопасности применения клексана
- ГЛАВА 4. ПРОФИЛАКТИКА НАРУШЕНИЙ СИСТЕМЫ ГЕМОСТАЗА И ПОСЛЕОПЕРАЦИОННЫХ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОГИНЕКОЛОГИЧЕСКИХ БОЛЬНЫХ
- 4. 1. Состояние системы гемостаза у онкогинекологических больных до операции
- 4. 2. Влияние фраксипарина и клексана на систему гемостаза у онкогинекологических больных
- 4. 3. Тромботические осложнения в послеоперационном периоде у онкогинекологических больных
- 4. 4. Оценка эффективности и безопасности применения низкомолекулярных гепаринов
- ГЛАВА 5. ПРОФИЛАКТИКА НАРУШЕНИЙ СИСТЕМЫ ГЕМОСТАЗА И ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ, ПОЛУЧАЮЩИХ ХИМИОТЕРАПИЮ
- 5. 1. Состояние системы гемостаза у онкологических больных до химиотерапии
- 5. 2. Диагностическая значимость различных показателей системы гемостаза
- 5. 3. Влияние низкомолекулярных гепаринов на систему гемостаза у онкологических больных, получающих химиотерапию
- 5. 3. Тромботические осложнения у онкологических больных, получавших химиотерапию
- 5. 4. Оценка эффективности и безопасности применения низкомолекулярных гепаринов
- ГЛАВА 6. ПРОФИЛАКТИКА И ЛЕЧЕНИЕ НАРУШЕНИЙ СИСТЕМЫ ГЕМОСТАЗА И ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ С ТРОМБОЗАМИ, ПОЛУЧАЮЩИХ ХИМИОТЕРАПИЮ
- 6. 1. Состояние системы гемостаза у онкологических больных с тромбозами до химиотерапии
- 6. 2. Влияние низкомолекулярных гепаринов на систему гемостаза у онкологических больных с тромбозами, получающих химиотерапию
- 6. 3. Рецидивирующие тромбозы у онкологических больных, получавших химиотерапию
- 6. 4. Оценка эффективности и безопасности применения низкомолекулярных гепаринов
- ГЛАВА 7. НАРУШЕНИЯ СИСТЕМЫ ГЕМОСТАЗА У
- ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ С ТРОМБОЗАМИ И ТРОМБОЭМБОЛИЕЙ ЛЕГОЧНОЙ АРТЕРИИ, РАЗВИВШИМИСЯ НА ФОНЕ ПОДОСТРОГО ДВС. КРОВИ
- 7. 1. Состояние системы гемостаза у онкологических больных до развития тромбоза и ТЭЛА
- 7. 2. Изменения системы гемостаза у онкологических больных с тромбозами и ТЭЛА, развившимися на фоне подострого ДВС крови
- 7. 3. Изменения функциональных свойств тромбоцитов у онкологических больных с тромбозами и ТЭЛА, развившимися на фоне подострого ДВС крови
- 7. 4. Результаты применения низкомолекулярных гепаринов у больных с тромбозами и ТЭЛА
- 7. 5. Оценка эффективности и безопасности применения низкомолекулярных гепаринов
- ГЛАВА 8. ОПРЕДЕЛЕНИЕ АНТИ-ХА АКТИВНОСТИ У
- ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ
Список литературы
- Баркаган З.С. Патогенез, диагностика и принципы терапии ДВС-синдрома//Materia Medica.-1997.-Nl (13). С.5−14.
- Баркаган З.С., Момот А. П. Основы диагностики нарушений гемостаза.-М., 1999. -196с.
- Баркаган З.С., Цывкина Л. П., Момот А. П., Шилова А. Н. Ошибки, просчеты и' пути совершенствования клинического применения низкомолекулярных гепаринов// Клиническая фармакология и терапия.-2000.-Т. 11 .-N. 1 .-С.78−83.
- Баркаган З.С. Очерки антитромботической фармакопрофилактики и терапии.- М.: Ньюдиамед, 2000.- 148 с.
- Баркаган З.С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза.- М.: Ньюдиамед, 2001.- 296 с.
- Бокарев И.Н., Попова Л. В. Венозный тромбоэмболизм и тромбоэмболия легочной артерии. М.: медицинское информационное агентство, 2005.-208 с.
- Вавилова Т.В. Антитромботическая терапия и методы ее лабораторного контроля (лекция) // Клиническая лабораторная диагностика.-2004.-К12.-С.21~32.
- Вавилова Т.В. Гемостазиология в клинической практике (пособие для врачей).- СПб.: Издательство СПбМУ им. акад. И. П. Павлова, 2005.- 92с.
- Воробьев П.А. Актуальный гемостаз.- М.: Ньюдиамед, 2004.- 140с.
- П.Воробьева Н. А., Пономарева И. А. К вопросу о распространенности венозного тромбоэмболизма // Тромбоз, гемостаз и реология.- 2007.-N2.- С.65−73.
- Гемостаз. Физиологические механизмы, принципы диагностики основных форм геморрагических заболеваний / Под редакцией Н. Н. Петрищева, Л. П. Папаян.- СПб., 1999.-С.93−111.
- Дворецкий Л.И. Паранеопластические синдромы//Справочник поликлинического врача.-2003.-Т.З .-N.3 .-С.135−141.
- Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция / Под ред. Н. Н. Петрищева.- СПб.: Изд-во СПбГМ, 2003.-184с.
- Долгов В.В., Свирин П. В. Лабораторная диагностика нарушений гемостаза. Тверь: Издательство «Триада», 2005.-227с.
- Евтюхин А.И., Соколовская Н. Е., Леоненков В. В., Утешева М. А. Профилактика тромбоза глубоких вен и тромбоэмболии легочной артерии у онкологических больных // Современная онкология.-2001.-T.3-N.2.-C.45−50.
- Карпачева Е.С., Титаева Е. В., Добровольский А. Б. и др. Роль Д-димера в диагностике венозных тромбозов и эмболий у терапевтических больных// Терапевтический архив.-2001 .-Т.73 .-N 8.-С.16−19.
- Кузник Б.И. Физиология и патология системы крови. Чита, 2004.230 с.
- Левин Т.Я., Ежов И. Ю., Соснина А. Н., Шевц Р. Л. Оценка эффективности и безопасности длительного применения клексана после эндопротезирования тазобедренного сустава// Тромбоз, гемостаз и реология.-2003.-М.4-С.62−65.
- Летаген С. Гемостаз и геморрагические заболевания: Пер. с англ.-М., 2004.-183 с.
- Лычев В.Г. Диагностика и лечение диссеминированного внутрисосудистого свертывания крови.- 2-е изд. Н. Новгород: издательство НГМА, 1998.-191 с.
- Маслихова В.Н. Профилактика тромботических осложнений при хирургическом лечении онкогинекологических больных: Дис.канд. мед. наук.- М., 1991.-136 с.
- Момот А.П., Елыкомов Е. А., Баркаган З. С. Методика и клиническое значение паракоагуляционного фенантролинового теста//Клиническая лабораторная диагностика.-1996.-N.4.-C. 17−20.
- Момот А.П. Принципы методы и средства лабораторной диагностики патологии гемостаза на современном этапе//Лабораторная диагностика.-2004.-М.2.-С.52−70.
- Момот А.П. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. СПб., 2006.-208с.
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии М.: Издательство «Спорт и культура», 1999.- 464 с.
- Папаян Л. П. Особенности диагностики тромбофилии //Лаборатория.-2000.-N.3.-C.12−13.
- Папаян Л. П, Князева Е. С. Д-димер в клинической практике (пособие для врачей)/ Под ред. Н. Н. Петрищева, — М., 2002.-20с.
- Петрищев Н.Н., Власов Т.Д.Физиология и патофизиология эндотелия//Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция // Под ред. Н. Н. Петрищева, СПб., 2003.С.4−38.
- Претромботическое состояние. Тромбоз и его профилактика / Балуда В. П., Балуда М. В., Гольдберг А. П. и др. М.: Зеркало-М., 1999.-297с.
- Рагимов А.А., Алексеева JI.A. Синдром диссеминированного внутрисосудистого свертывания крови: учебное пособие для врачей. М.: Практическая медицина, 2005.-С.62.
- Рак и тромбоз / Балуда В. П., Балуда М. В., Тлепшуков И. К., Цыб А.Ф.-Москва Обнинск, 2001.-153 с.
- Шитикова А.С. Тромбоцитарный гемостаз.- СПб.:2000.-158 с.
- Шиффман Ф.Д. Патофизиология крови: Пер. с англ.- М.: СПб. Издательство БИНОМ Невский диалект, 2000.-С.247−269.
- Achcar A., Laaban G.P., Horellou М.Н. et al. Prospective screening for occult cancer in patients with venous thromboembolism// Thrombosis and Haemostasis.-1997.-(Suppl).-OC-P. 1564.
- Agnelii G. Venous thromboembolism and cancer: two-way clinical association// Thrombosis and Haemostasis.-1997.-V.78.-N.l.-P.l 17−120.
- Agnelii G., Prandoni P., Santamaria M.G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis//New.Eng. J.Med.-2001 .-V.345.-P. 165−169.
- Ahmed Z., Mohaddin Z. Deep vein thrombosis as a predictor of cancer// Angiology.-1996.-V.47.-P.261 -265.
- Alikhan R., Peters F., Wilmott R. et al. Epidemiology of fatal pulmonary embolism in non-surgical patients (abstract)//Blood.-2002.-V.100.-P.276.
- Arcelus J.I. Recognizing the risk of VTE in surgical patients //International Surgical Thrombosis Meeting «Optimizing VTE Management in surgical patients» (abstract).-Greece, 2007.
- Arkel Y.S. Thrombosis and cancer//Semin.Oncol.- 2000.-V.27.-P.362−374.
- Baron J.A., Gridley G., Weiderpass E. et al. Venous thromboembolism and cancer//Lancet.- 1998.-V.351.- P.1077−1080.
- Bastounis E.A., Karayiannakis A.J., Marki G. er al. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study//! Int. Med.-1996.-V.239-P. 153−56.
- Bauer K.A., Levine M. Evaluation and management of the cancer patient with thrombosis// American Society of Clinical Oncology.- 1999.-P.223−235.
- Bauer К.A. Management of thrombophilia//J.Thromb. Haemost.-2003.-V.1.-N.27-P.1429−1434.
- Becker R.C., Fintel D.J., Green D. Antithrombotic therapy.-2th ed. U. S. A.- 2002.-352 P.
- Bergmann J.F., Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients/ZHaemostasis.- 1996.-V.26 (Suppl.2).-P.16−23.
- Bergmann J.F., Mouly S. Thromboprophylaxis in medical patiens: focus of France// Semin. Thromb.Haemost.- 2002.-V.28 (suppl).- P.51−55.
- Bergqvist D., Lowe G.D.Berstad A et al. Prevention of venous thromboembolism after surgery: a review of enoxaparin// Br. J. Surg.-1992.- V.79.- N 6.-P. 496−498.
- Bergqvist D., Burmark U.S., Flordal P.A. et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 units in 2070 patients//Br.J.Surg.-1995.-V.82.-P.496−501.
- Bergqvist D. Venous thromboembolism and cancer: prevention of VTE//Thromb.Res.-2001 .-V. 102.-P.209−213.
- Bjerkeset O., Larsen S., Reiertsen O. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism duringdigestive surgery: play the winner designed study//World J.Surg.- 1997.-V.21.-P.584−588.
- Bouma B.N., Meijers J.C.M. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis // Thromb Haemost.-1999.-V.82.-P.243−250.
- Bratzler D.W. Underuse of venous thromboembolism prophilaxis for general surgery patients: physician practices in the community hospital setting//Arch.Intern.Med.-1998.-V. 15 8 .-P. 1909−1912.
- Brill-Edwards P., Lee A. D-dimer testing in diagnosis of acute venous thromboembolism//Thromb. Haemost.-1999.-V.82.-N.2.-P.688−694.
- Bromberg M.E., Cappello M. Cancer and blood coagulation: molecular aspects // Cancer.-l999.-V.3.-P. 132−138.
- Buccheri G., Ferrigno D., Ginardy C. et al. Haemostatic abnormalities in lung cancer: prognostic implications//Eur.J.Cancer.- 1997.-V.33.-P.50−55.
- Buller H.R., Agnelii G., Hull R.D. et al. Antithrombotic Therapy for Venous Thromboembolic Disease. The Seventh ACCR Conference on Antithrombotic and Thrombolytic Therapy//Chest.- 2004.-V.126.-P.401S-428S.
- Buller H.R., Sohne M., Middeldorp S. Treatment of venous thromboembolism//JHT.- 2005.-V.3.-N.8.-P.1554−1560.
- Cade J.P. A randomized double-blind study between a low molecular weight heparin Kaby 2165 and standard heparin deep in the prevention of deep vein thrombosis in general surgery: a French multicenter trial// Thromb.Haemost.-1998.-V.59.-P.216−220.
- Caprini J.A., Botteman M.F., Stephens J.M. et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States// Value Health.-2003.-V.6.-P.59−74.
- Cicco M. The prothrombotic state in cancer: pathogenic mechanisms//Crit Rev Oncol Hematol.-2004 Jun.-50 (3).-P. 187−196.
- Ciccone W.J., Fox P. S., Neumyer M. et al. Ultrasound surveilance for asymptomatic deep venous thrombosis after total joint replacement//J.Bone It Surg.- 1998.- V.80A.-P.1167−1174.
- Clagett G.P., Anderson F.A., Heit J., et al. Prevention of venous thromboembolism//Chest.-l 995.-V. 108.-P.312−334.
- Cohen A.T. Venous thromboembolic disease management of the nonsurgical moderate-and high-risk patient//Semin Haematol.-2000.-V.37 (suppl.).-P. 19−22.
- Cohen A.T., Alikhan R. et al. Venous thromboembolism risk assessment in medical patients (abstract) //Blood.- 2002.-V.100.-P.280a.
- Colman R.W. Biologic activities of the contact factors in vivo // Thromb-Haemost. -1999.-V.82 .-P. 1568−1577.
- Comuz G., Pearson S.D., Creager M., et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis//Ann. Intern. Med.-1996.-V125.-785−93.
- Couson F., Bounameaux C., Didier D et al. Influence of variability of interpretation of contrast venography for screening of postoperative deep vein thrombosis on the results of a thromboprophylactic study// Thromb.Haemost.-1993 .-V.70.-P.573−575.
- Cushman M., Costantino J.P., Bovill E.G. et al. Effect tamoxifen on venous thrombosis risk factors in women without cancer: the breast cancer prevention trial//Br. J. Haematol:-2003 .-V. 120 (1).- P.109−116.
- Daly E., Vessey M.R., Hawkins M.M. et al. Risk of venous thromboembolism in users of hormone replacement therapy/ZLancet.-1996.-V.348.-P.977−978.
- De Lissovoy G., Subedy P. Economic evaluation of enoxaparin as profilaxis agains venous thromboembolism in seriously ill medical patients: a US perspective//Am.J.Vanag.Care.-2002.- V.8.-P. 1082−1088.
- De Stefano V., Martinelli I., Manucci P.M. et al. The risk of recurrent deep venous thrombosis among heteroxygous carries of both factor V Leiden and the G20210A protrombin mutation//New Engl.J.Med.- 1999.-V.341.-P.801−806.
- Deitcher S.R. Primary prevention of venous thromboembolic events (VTE) in the cancer patient: an American survey study// American Society of Clinical Oncology, 41 Annual Meeting May 13−17. 2005.-P. 746.
- Di Micco P., Romano M., Niglio A. et al. Alteration of haemostasis in non-metastatic gastric cancer // Dig. Liver Dis.-2001 Oct.-V.33 (7).-P.546−50.ф 90. Donati М.В. Cancer and thrombosis// Haemostasis.-1994.-V.24.-P.128 131.
- Douketis J.D., Kearon C., Bates S. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism//JAMA.-1998.- V.279.-P.458−462.
- Egger В., Shhmid S.W., Naef M. et al. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients //Dig.Surg.- 2000.- V.17.-P.602−609.
- Eichiger S., Minar E., Hirschi M. et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210 transition in the prothrombin gene// J.Thromb.Haemost.-1999.-V.81.-P.14−27.
- Eilertsen K.E., Osterud B. Tissue factor: pathophisiolody and cellular biology // Bood Coagul. Fibrinolysis.- 2004.- V.15 (7).-P.521−538.
- Elsayegh D., Elhaij A., Emmer L., Teryanian T. Frequency and prognostic significance of DVT with specific neoplasms// American Society of Clinical Oncology, 41 Annual Meeting May 13−17.- 2005.-P.781.
- Falanga A., Tickles FR. Pathophysiology of the thrombotic state in the cancer patient//Semin Thromb Haemostas.-1999.-Y.25.-P. 173−182.
- Falanga A., Vignoli A. Venous thromboembolism in oncology // Eksp. Oncol. 2004.- V. 26 (1).- P. 11−14.
- Folkman J. Tumors angiogenesis and tissue factor// Nat. Med.- 1996.-V.2.-P.167−168.
- Francis C.W., Felcher A.H., White J. et al. Thrombin activity associated with indwelling central venous catheters // Thrombosis and Haemostasis.-1997.-V.77.-P.48−52.
- Freedman K.B., Brookenthal K.R., Fitzgerald R.H. et al. A metaanalysis of thromboembolic prophylaxis following elective total hip arthroplasty//J.Bone Joint.Surg.Am.- 2000.-V.82.-P.929−938.
- Friedman R. Duration of prophylaxis for venous thromboembolism after total hip and knee arthroplasty: finding from the Global Orthopaedic Registry //J.Thromb.Haemost.-2003.-V.l 15.-P.1436.
- Gaine G.J., Harris A.L., Christodoulos K. et al. Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer // Cancer Lett.- 2005.-V.219 (2).-N.10.-P.163−167.
- Gallus A.S. Prevention of post-operative deep leg vein thrombosis in patients with cancer// Thrombosis and Haemostasis.-1997.-V.78.-P. 126 132.
- Geerts W.H., Heit J.A., Clagett G.P. et al. Prevention of venous thromboembolism//Chest.-2001 .-V. 119.-P. 132S-" 175S.
- Geerts W.H., Pineo G.F., Heit J.A. et al Prevention of venous thromboembolism The Seventh ACCR Conference on Antithrombotic and Thrombolytic Therapy//Chest.- 2004.-V.126 (Suppl).-P.338S-400S.
- Gouin-Thibault I., Samama M.M. Laboratory diagnosis of the thrombophilie state in cancer patients // Semin Thromb Haemostas.-1999.-V.25.-P. 167−172.
- Green K.B., Silverstein R.L. Hypercoagulability in cancer.// Hemat. One. Clin.North. AM.-1996.-V.10.-P 499−530.
- Guidelines on diagnosis and management of acute pulmonary embolism. Task Force Report. European Society of Cardiology/ZEurop.Heart J.-2000.-V.21.-P.1301-, 1336.
- Guidelines or Antithrombotic Therapy for Prevention and Treatment of Thrombosis. The Sixth (2000) ACCR//Chest.- 2001.-V.119 (Suppl.l).-370P.
- Haas S.K. Venous thromboembolic risk and its prevention in hospitalized medical patients//Semin.Thromb.Haemost.-2002.-V.28.-P.577−583.
- Harenberg J., Roebruck P., Heene D.L. et al. Subcutaneus low molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients// Haemostasis.-1996.-V.26.-P.127−139.
- Harenberg J., Schomaker U., Flosbach C.W. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical inpatients at increased thromboembolic risk (abstract)//Blood.-1999.-V.94(Suppl).-P.399a.
- Harry R.B., Agnelii G., Hull R.D. et al. Antithrombotic Therapy for Venous thromboembolic Disease. The Seventh ACCR Conference on Antithrombotic and Thrombolytic Therapy//Chest.- 2004.-V.126.-P.401 S-428S.
- Heit J.A., Silverstein M. D, Mohr D.N. et al. Predictors of survivalafter deep vein thrombosis and pulmonary embolism: a population-based, cohort study//Arch.Intern.Med.-1999.-V. 159.-P.445−453.
- Heit J.A., Silverstein M. D, Mohr D.N. et al. Risk factors of deep vein thrombosis and pulmonary embolism: a population-based, control study//Arch.Intern.Med.-2000.-V. 160.-P.809−815.
- Heit J.A., Silverstein M. D, Mohr D.N. et al. The epidemiology of venous thromboembolism in the community//Thromb.Haemost.-2001.-V.86.-P.452−463.
- Hejna M., Raderer M., Zielinsky C.C. Inhibition of metastasis by anticoagulants // J. Nalt. Cancer Inst.-1999.-V.91.-P. 22−36.
- Hillen H.F. Thrombosis in cancer patients// ESMO, Annual, of oncology.- 2000.-V.1 l (suppl.3).-P.273−276.
- Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to Anticoagulant therapy: Heparin. A Statement for healthcare Professionals from the American Heart Association//Curculation.-2001.-P.2994−3018.
- Hull R.D., Brand R.F., Pineo G.F. et al. Preoperative vs postoperative initiation of low molecular weight heparin prophilaxis against venous thromboembolism in patients undergoing elective hip replacement// Arch.Intern.Med.-l 999.-V. 159.-P. 137−141.
- Hull R.D. Thromboprophylaxis: when to finish// International Surgical Thrombosis Meeting «Optimizing VTE Management in surgical patients» (abstract).-Greece, 2007.
- Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer //N.Engl. J.Med.-2004.-V.350.-P.2335−2342.
- Hyers T.M., Agnelii G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease//Chest.-1998.-V.l 14/5 (Suppl).-P.561−578.
- Hyers T.M., Agnelii G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease//Chest.-2001 .-V.l 19 (Suppl.l).-P.176.
- Ikeda M., Iwamoto S., Imamura H. et al. Increased platelet aggregation and production of platelet — derived microparticles after surgery for upper gastrointestinal malignancy // J. Surg.Res.- 2003.-V.115 (2).-P. 174−183.
- Jacquemin M., Saint-Remy J.M. The of antibodies to coagulation factors for anticoagulant therapy// Curr. Med Chem.- 2004.-V.il (17).-P. 2291−2296.
- Kakkar A.K., Boecki O., Boneu B. et al. Efficacy and safety of a low molecular weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial//World.J.Surg.-1997.- V.21.-P.2−8.
- Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins// Haemostasis.-1997.-V.27 (suppl. l).-P.32−37.
- Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer patients//Seminars in Thrombosis and Haemostasis.-1999.-V.25 .-N 2.-P.239−243.
- Kakkar A.K., Haas S., Walsh D. et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery (abstract)// Thromb.Haemost.-2001.-V.86 (suppl).-P.0cl732.
- Kakkar A.K., Kadziola Z., Willamson R.C.N. et al. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer (abstract)//Blood.-2002.-V. 100.-P.148a.
- Kakkar A.K., Haas S., Walsh D. et al. Compliance with recommended prophylxis for venous thromboembolism: improving the use and rate ofuptake of clinical practice guidelines//J.Thromb.Haemost.-2004.-V.2.-P.221−227.
- Kalodici E.P., Hoppensteadt D.A., Nicolaides A.N. et al. Deep venous thrombosis prophylaxis with low molecular weight venous thrombosis //Ins.Angiol.-1996.-V. 15.-P. 162−168.
- Kamphuisen P.W., Eikenboom J.C.J., Vos H.L. et al. Increased levels of factor VIII and fibrinogen in patients .with venous thrombosis are not caused by acute phase reactions//J.Thromb.Haemost.-1999.-V.81.-P.680−683.
- Kappermayer J., Nagy B.J., Miszti-Blasius K. et al. The emerging value of P-selectin as a disease marker // Clin. Chem. Lab. Med.- 2004,-V. 42 (5).-P. 475−486.
- Kearon C., Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively//Arch.Intern.Med.-1995.-V.155.-P.366−372.
- Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism//New ENGJ.Med.-1999.-V.349.-P.901−907.
- Kearon C. Noninvasive diagnosis of deep vein thrombosis in postoperative patients//Semin.Thromb.Haemost.-2001 .-V.27.-P.3−8.
- Kearon C., Salzman E.W., Hirsh J. Epidemiolody, pathogenesis, and natural history of venous thrombosis/Hemostasis and thrombosis: basic principles and clinical practice.4th edition.-Philadelphia: Lip-pincott Williams and Wilkins, 2001.-P. 1153−1178.
- Kearon C. Natural history of venous thromboembolism//CircuIation.-2003 .-V. 107.-P. 122−130.
- Koch A., Bouges S., Ziegler S. et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous. meta-analyses//Br.J.Surg.-1997.-V.84.-P.750−759.
- Koster Т., Rosendaal F.R., Briet E. et al. Protein С deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)//Blood.-1995.-V.85.-P.2756−2761
- Kraaijenhagen R.A., Anker P. S., Koopman M.M. et al. High plasma concentration of factor Vatic is a major risk factor for venous thromboembolism//J.Thrombos.Haemost.-2000.-V.83.-P.5−9.
- Kuenen B.C., Rosen L., Smit E.f. Dose-finding and pharmacokinetic study of cisplatin, gemicitabine and SU5416 in patients with solid tumors// J.Clin.Oncol.-2002.-V.20.-P.6−95.
- Lassen M.R., Borris L.C., Backs S. et al. Clinical limitations of risk assessment models//Blood.Coagul.Fibrinolis.-1999.-V. 10 (suppI).-P.S45-S51.
- Lausen I., Jensen R., Jorgensen L.N. et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis//Eur.J.Surg.-1998.-V.164.-P.657−663.
- Lechner K., Kyrle P.A. Antithrombin III concentrates-are they clinically usefull//Thromb.Haemost.-1995.-V.73.-P.340−348.
- Lee A.J., Levine M.N. The thrombophilic state induced by therapeutic agents in cancer patients.// Semin Thromb Haemostas.-1999.-V.25.-P.137−145.
- Lee A.J. Treatment strategies for venous thromboembolism in the cancer patient// American Society of Clinical Oncology, 2001.-P.309−315.
- Lee A.J., Levine M.N. Venous thromboembolism and cancer: risks and outcomes//Circulation.-2003 .-V. 107.-P.117−121.
- Lee A.J., Levine M.N., Baker R.I. et al. Low molecular weight heparin versus coumarin for the prevention recurrent venous thromboembolism in patients with cancer//N.Engl.J.Med.-2003.-V.349.-P.146−153.
- Leichler E., Schramm W., Flosbach C.W. et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy /safely profile of a low molecular weight heparin (enoxaparin)//Haemostasis.-1996.-V.26 (suppl).-P.49−56.
- Lencing A.W., Prins M.H., Davidson B.L. et al. Treatment of deep venous thrombosis with low- molecular -weight heparins: a metaanalysis//Arch. Intern. Med.-1995.-V.5155.-P.601−607.
- Levi M., Jonge E., Poll Т., Cate H. Disseminated intravascular coagulation// Thrombosis and Haemostasis.-1999.-V.82 (2).-P.695−705.
- Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy// Thrombosis and Haemostasis.-1997.-V.78.-P.133−136.
- Levine M.N., Rickles F., Kakkar A.K. Thrombosis in cancer patients// American Society of Clinical Oncology, 38 Annual Meeting, Orlando -2002.-May 18−21.- P.57−60.
- Levine M.N., Lee A.Y., Kakkar A. K Thrombosis and cancer.// American Society of Clinical Oncology, 41 Annual Meeting. 2005.-May 13−17.-P. 748- 577.
- Levitan N., Dowlaty A., Remick S. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data//Medicine.-l 999.-V.78.-P.285−291.
- Lin P.P., Graham D., Hann L. et al. Deep venous Thrombosis after orthopedic surgery in adult cancer patients //J. Surg. Oncol.- 1998.-V.68.-N1.-P.356−360.
- Lip J.A., Chin B.S., Blann A.D. Cancer and the prothrombotic state // Lancet Oncol.- 2002 Jan.- V.3 (1).- P.27−34.
- Lloid A., Anderson P., Quinian D.J. et al. Economic evaluation of prophylaxis of venous thromboembolism in acute medical patients with enoxaparin in the U.K. (abstract)//Blood.-2000.-V.96.-P.847a.
- Loreto M.F., Martinis D.E., Corsi M.P. et al. Coagulation and cancer: implications for diagnosis and management// Pathology oncology research.-2000.-V.6.-N.4.- P.302−312.
- Lutz L., Haas S., Hach-Wunderle V. et al. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis: publication for the specialist platform//Med.Welt.-2002.-V.53.-P.231−234.
- Lykke J., Nielsen H.J. Haemostatic alterations in colorectal cancer: perspectives for future treatment // Surg. Oncol. -2004.-V.88 (4).-N.5.-P.269−275.
- Managing Oral Anticoagulant Therapy//Chest.-2001 .-V. 119.-P.22−28.
- Mannucci P. Markers of hypercoagulability in cancer patients//Haemostasis/-1997.-V.27.-P.25−31.
- Martincic D., Kravtsov V., Gailani D. Factor XI messenger RNA in human platelets //Blood.-1999.-V.94.-P.3397−3404.
- Meyers G., Mecklenburg L.H., Boom N.B. et al. High levels of coagulation factor XI as a risk factor for venous thrombosis//New.Engl.J.Med.-2000.-V.342.-P.696−701.
- Meyers G., Marjanovic Z., Valcke J. Et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer//Arch. Intern. Med. -2002.-V 162.-P. 1729−173 5.
- Mimetic P., Laborite S., Damon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeiy//Br.J.Surg.-2001.-V.88.-P.913−930.
- Mismetti P., Laporte-Simitsidis S. Tardy B. Et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a metaanalysis of randomized clinical trials//Thromb.Haemost.-2000.-V.83.-P.14−19.
- Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention pf venous thromboembolism in general surgery // Br. J. Surg.-2001.-V.88.-P.913−930.
- Mousa S.A. Antithrombotic in thrombosis and cancer // Expert. Rev. Cardiovascular. There. 2003. — V. l (2).-P. 283−291.
- Mousa S.A. Low-molecular-weight heparins in thrombosis and cancer: emerging links // Cardiovasc. Drug. Rev.-2004.-V.22 (2).- P. 121 134.
- Mousa S.A. Low-molecular-weight heparins in thrombosis and cancer // Semin. Thromb Haemostas.-2004.-V.30 suppl.l.- P. 25−30.
- Nappo F., De Rosa N., Marfella R. et al. Impairment of endothelial functions by acute Hyperhomocysteinemia and reversal antioxidant vitamins//JAMA.-1999.-V.281 .-P.2113−2118.
- Naschitz J.E., Yeshurun D., Eldar S., et al. Diagnosis of cancer-associated vascular disorders// Cancer.-1996.-V.77.-P. 1759−67.
- Nicolaides A.N. et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int.Angiol.-2006.-V.25.-P.101−161.
- Nurmohamed M.T., Verhaeghe R., Haas S. et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery//Am.J.Surg.-1995.-V.169.-P.567−571.
- Oberhoff C., Rollwagen C., Tauchert AM et al. Perioperative development of a thrombotic risk profile in patients with carcinomas of the breast: a cause of increased thrombosis // Eur. J. Gynaecol. Oncol.-2000.-V.21 (6).-P.560−568.
- Ornstein D.L., Zacharski L.R. The use of heparin fir treating human malignancies //Haemostasis.-1999.- V.29 (suppl).-P.48−60.
- Piccioli A., Prandoni P., Ewenstein B.M., Goldhaber S.Z. Cancer and venous thromboembolism//Am. Heart J.- 1996.-V.132.-P.850−855.
- Pineo J.F., Hull R.D. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases //Eur. J. Med.Res.-2004.-V.30.-N.9 (4).-P.215−224.
- Prandoni P., Lensing A.W., Buller H.R., et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer// New Engl.J.Med.-1992.-327.- P. l 128−33.
- Prandoni P., Lensing A., Cogo A. et al. The long-term clinical course of acute deep vein thrombosis//Ann.Intern.Med.-1996.-V.125.-P.l-7.
- Prandoni P. Antithrombotic strategies in patients with cancer// Thrombosis and Haemostasis.-1997.-V.78.-P.141−144.
- Prandoni P., Lensing A., Piccioli A. et al. Ultrasonography of contralateral veins in patients with unilateral deep-vein thrombosis// Lancet.-1998.-V.352. P.786.
- Prandoni P., Piccioli A., Georama A. Cancer and venous thromboembolism: an overview.// HematoIogica.-1999.-V.84.-P.437−445.
- Prandoni P., Lensing A., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis//Blood.-2002.-V.100.-P.3484−3488.
- Prandoni P., Lensing A., Prins M.H. et al. Residual venous thrombosis as predictive factor of recurrent venous thromboembolism//Ann.Intern.Med.-2002.-V.137.-P.955−960.
- Prevention of venous thromboembolism. International consensus statement. (Guidelines According to Scientific Evidence) Int. Angiol-1997.- V.16.-P.3−28.
- Prins M.H., Hettiarachchi R.J.K., Lensing A., Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? // J.Thromb.Haemost.-1997.-V.78.-P.121−125.
- Pulmonary Embolism-New Paradigms in diagnosis and Therapy//Chest.- 2001 .-V. 120.-P. 1556−1561.
- Ranee A., Emmerich J., Glued C., et al. Occult cancer in patients with bilateral deep- vein thrombosis// Lancet.-1997.-V.350.-P. 1448−9.
- Rasmussen M.S. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis//Cancer Treat.Rev.-2002.-V.28.-P. 141 -144.
- Rasmussen M. S, Willie-Jorgensen P., Jorgensen L.N. et al. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy (abstract)//Blood.-2003.-V.102.-P.56a.
- Rickles F., Falanga A. A Molecular basis for the relationship between thrombosis and cancer//Thromb.Res.-2001.-V.102.-P.215−224.
- Rickles F., Levine M.-Epidemiology of thrombosis and cancer//Acta haemat.-2001.-V.106.-P.6−12.
- Roberts HR, Monroe DM, Oliver J.A. et al. Newer concepts of blood coagulation//Haemophilia.-1998.-V.4.-P.331−334.
- Rodger M., Wells P. S. Diagnosis of pulmonary embolism// Thromb.Res.-2001 .-V. 103.-P.225−238.
- Rosendaal F.R. Risk factors for venous thrombotic disease//J. Thromb.Haemost.-1999.-V.82.-P.610−619.
- Rosenzweig M.Q., Bender C.M., Lucke J.P. et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J. Pain Symptom Manage.-2004.-V.27.-P.185−190.
- Sadler J.E. von Willebrand factor: two sides of a coin //J. Thromb. Haemost.-2005 .-V.3 .-P. 1702−1709.
- Sallah S., Wan J.Y., Nquyen N.P. et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study// Thromb.Haemost.-2001 Sep.-V.86 (3).-P.828−833.
- Sallah S., Wan J.Y., Nquyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics// Thromb.Haemost.-2002.~V.87.-P.575−579.
- Sallah S., Husain A. Sigounas V. et al. Plasma. coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy//Clin. Cancer Res.- 2004.-V.10 (21).-N.l.-P.7238−7243.
- Salvati E.A., Pellergini V.D., Sharrock H.N. et. al. Recent advances in venous thromboembolic prophilaxis during and after total hip replacement: Symposium//! Bone Jet. Surg. 2000. — V. 82A.-P. 252 270.
- Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients//N.Engl.J.Med.-1999.- V.341.-P.793−800.
- Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study//Ann.Intern.Med.-2000.-V.160.-P.3415−3420.
- Schulman S., Rhedin A.S., Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulation after a first episode of venous thromboembolism//N.Engl.J.Med.-1995.- V.332.-P.1661−1665.
- Schulman S., den Heijer M., Nys A.M. Thrombosis prophylaxis in hospitalized medical patients: does prophylaxis in all patients make sense?// Neth. J.Med.-2000.- V.56.-P. 171 -176.
- Simmonds R.E., Lane D.A. Regulation of coagulation. In: Loscalzo J. Schafer AL, eds. //J. Thrombosis and Hemorrhage.2nd ed. Baltimore, Md: Williams and Wilkins.- 1998.- P.46.
- Smorenburg S.M., Hutten B.A., Prins M.N. Should patients with venous thromboembolism and cancer be treated differently? // Haemostasis.-1999.-V.29 (suppl).-P.91 -97.
- Solis M.M., Ranval T.J., Nix M.L. et al. Is anticoagulation indicated for asymptomatic postoperative calf vein thrombosis? // J.Vasc.Surg.-1992.- V.16.-P.414−418.
- Sorensen M.T., Mellemkjaer L., Steffensen F.H. et al. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism//N. Engl. J. Med.- 1998.-V.338.-P.l 169−1173.
- Tait R.C., Walker I.D., Perry D.J. et al. Prevalence of antithrombin deficiency in healthy population//Brit.J.Haemat.-1994.- V.87.-P.106−112.
- Tempelhoff G.F., Dietrich M., Hommel G., Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer // J.Clin. Oncol.-1996.-V. 14.- P.2560−2568.
- Tesselaar M., Steeghs N., Rosendaal F., Osanto S. Incidence of thrombosis in gastro-esophageal cancer- a cohort study of 761 patients// American Society of Clinical Oncology, 41 Annual Meeting May 13−17.-2005.-P. 779.
- Thodiyil P.A., Kakkar A.K. Variation in relative risk of venous thromboembolism in different cancers//Throm.Haemost.-2002.-V.87.-P.1076−1077.
- Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris// London: New Sydenham Society. -1872.-P.281−295.
- Turkstra F., Koopman M.M., Buller H.R. The treatment of deep vein thrombosis and pulmonary embolism//Thromb.Haemost.-1997.-V.78.-P.489−496.
- Tveit D.P., Hypolite I.О., Hshieh P. et al. Chronic dialysis patients have high risk for pulmonary embolism//Am.J.Kidney.Dis.-2002.-V.39.-P1011−1017.
- Van Boven H.H., Vandenbrouchke J.P., Westendorp R.G. Rosendaal F.R. Mortality and causes of death in inherited antithrombin deficiency//J.Thromb.Haemost.-1997.-V.77.-P.452—455
- Van Tuiburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis//Blood.-2002.-V.95.-P.285 5−2859.
- Viale P.H., Schwartz R.N. Venous thromboembolism in patients with cancer. Part II. Current treatment strategies // Clin. J. Oncol. Nurs. -2004.- V.8 (5).-P.465−469.
- Von Tempelhoff G.F., Dietrich M., Niemann F. et al. Blood coagulation and thrombosis in patients with ovarian malignancy //Thromb. Haemost.-1997.-V.77.-P.456−461.
- Walsh P.N. Platelets and factor XI bypass the contact system of blood coagulation//J. Thromb. Haemost.-1999.-V.82.-P.234−242.
- Weitz J.C. Low-molecular-weight heparins // N Engl. J. Med. 1997.-V.337.-P.688−698.
- Weitz J.C., Israel V.K., Waisman J.R. et al. Chemotherapy induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation // J. Thromb. Haemost.-2002.Aug.--V.88(2).-P.213−220.
- Westrich G.H., Haas S.B., Mosca P. et al. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty//J.Bone Joint.Surg.Br.-2000.-V.82.-P.795−800.
- White R.H., Zhou H., Romano P. S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures//Throm.Haemost.-2003.-V.90.-P.446−455.
- Zacharski L.R., Ornstein D.L. Heparin and cancer //Thrombos.Haemost.-1998.-V.80.-P. 10−23.
- Zacharski L.R., Prandoni P., Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients// The oncologist.-2005.-V.10.-N.1- P.72−79.
- Zakarija A., Kwaan H.C. Bleeding and thrombosis in cancer patients //Expert Rev.Cardiovasc.Ther.-2003 Jul.-V.l (2).-P.271−281.
- Ziegler Т., Murzik M., Schau A. et. al. Interpretation of increased D-dimer values // Hamostaseologie.-2004.- V. 24 (2).-P. 144−146.
- Zoller В., Berntsdotter A., de Frutos G.P., Dahlback B. Resistance to activated protein С as an additional risk factor in hereditary deficiency of protein S//Blood.-1995.-V.12.-P.3518−3553.
- Zoller В., de Frutos G.P., Hillarp A., Dahlback B. Thrombophilia as multigenic disease//Haematologica.-1999.-V.84 (l).-P.59−70.